Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in stage III non-small-cell lung cancer
SE Schild, PJ Stella, SM Geyer, JA Bonner… - International Journal of …, 2002 - Elsevier
Purpose: This Phase III study was performed to determine whether chemotherapy plus bid or
qd radiotherapy (RT) resulted in superior survival for patients with Stage III non-small-cell
lung cancer (NSCLC). Methods and Materials: Patients with Stage III NSCLC and an Eastern
Cooperative Oncology Group performance status of≤ 1 were randomized to receive either
standard qd RT (60 Gy in 30 daily fractions) or split-course bid RT (30 Gy in 20 fractions bid)
followed by a 2-week break and then 30 Gy in 20 fractions bid Both arms included etoposide …
qd radiotherapy (RT) resulted in superior survival for patients with Stage III non-small-cell
lung cancer (NSCLC). Methods and Materials: Patients with Stage III NSCLC and an Eastern
Cooperative Oncology Group performance status of≤ 1 were randomized to receive either
standard qd RT (60 Gy in 30 daily fractions) or split-course bid RT (30 Gy in 20 fractions bid)
followed by a 2-week break and then 30 Gy in 20 fractions bid Both arms included etoposide …
以上显示的是最相近的搜索结果。 查看全部搜索结果